Publication | Closed Access

Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the integrins αvβ3 and αvβ5 in patients with advanced solid tumours

OncologyPharmacologyAdvanced Solid TumoursTherapeutic EfficacyPharmacotherapyAnti-cancer AgentCancer TreatmentMedicineIntegrins αVβ3Emd 121974